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Summary.-The relationship between oestrogen-receptor protein (ER) content of
the tumour and the response to endocrine therapy was determined in 119 patients, in
a collaborative prospective study. Twenty-eight of the 80 patients with measurable
ER responded to treatment according to UICC criteria, compared with only 3/39
without ER. It was found that site of biopsy did not influence the result, but tumour
content of the tissue sample was significantly related to the presence of receptors.
The organizational problems of such a study are discussed.
RESULTS from a number of centres in
the United States and Europe indicate
thattheresponse ofadvanced breast cancer
to endocrine therapy can be correlated
with the oestrogen-receptor content of the
tumour (McGuire et al., 1975). In 1974 the
British Breast Group initiated a study to
investigate these reports in a prospective
series.
Two centres took part in our study, both
referring all patients suitable for endocrine
therapy over a 30-month period (1.10.74-
31.3.77). The clinicians were not informed
of the results of oestrogen-receptor assays,
and patients were treated according to the
routine protocols for each centre. Our
study included external clinical assess-
ment of response to therapy, pathological
review of all biopsy specimens, and a
comparison of laboratory methodology.
METHODS
Criteria for inclusion.-Consecutive un-
selected patients from Guy's Hospital and the
Royal Infirmary of Edinburgh breast clinics
were included in this study, provided theyhad
evidence of progressive, histologically con-
firmed, locally advanced or disseminated
breast cancer, and had a lesion accessible for
biopsy for the estimation of oestrogen-
receptor content. Most patients had not re-
ceived previous systemic therapy for ad-
vanced disease, but in the event of previous
additive hormone therapy, at least 14 days
were allowed to elapse before biopsy was
performed. Biopsy, from a single site, was
carried out immediately before new endocrine
therapy was started.
Pathological assessment.-Sections from
every biopsy specimen were examined by one
pathologist (R.R.M.) without knowledge of
the oestrogen-receptor assay result, to deter-
mine whether adequate tumour tissue was
present. An 8-point scoring system was de-
vised as follows:
(a) the overall proportion of neoplastic
tissue to normal tissue in the section
was allocated a score of 1 (<50 /) to
4 (100%)
(b) the proportion of malignant epithelial
cells to stroma within the neoplasm
was scored 1 (<50%) to 4 (100%).
These 2 scores were then added together.
Biopsy specimens scoring a total of 5 or more
were considered to contain adequate tumour;
tissues scoring 3 or 4 were doubtful; a tissue
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scoring 2 or less was considered inadequate.
For the purpose of this study, tissues with a
score of 2 or less were excluded from analysis.
No judgement could be made on whether the
section sent for review was representative of
the tissue used for the receptor assay.
The oestrogen-receptor (ER) assay.-Tu-
mours were assayed by the normal method for
each ofthe two laboratories (King et al., 1977;
Hawkins et al., 1975).
In principle both methods were similar,
using saturation analysis with separation by
dextran-coated charcoal to measure only un-
occupied soluble receptor sites. There were,
however, minor differences between the two
laboratories, as described below.
The biopsy specimens from the patients at
Guy's Hospital were transported in solid CO2
across London to the laboratory, and stored
in liquid N2 forup to 2 weeks before the assay.
The (supernatant) cytosol was prepared by
pulverizing the tumour slices immediately
after their removal from liquid N2, suspend-
ing the powder in buffer containing thio-
glycerol, followed bylow-speedcentrifugation.
Radioactive oestradiol-17B (final concentra-
tion 5 nM) was added, with or without non-
radioactive diethyl stilboestrol (final concen-
tration 500 nM) in buffer, the mixture in-
cubated overnight at 4°C and dextran-coated
charcoal suspension used to separate bound
from free fractions. Specific binding was
measured as the difference between the con-
trol and diethyl stilboestrol (DES) treated
samples.
In Edinburgh, the assay was always per-
formed on fresh tissue, transported on ice
directly from the operating theatre to the
nearby laboratory. The (supernatant) cytosol
was prepared by homogenization of the tu-
mour slice in Tris-buffer without any thiol
reagent, followed by low-speed centrifugation
at 4°C. Portions of supernatant were incu-
bated overnight at 4°C with a fixed concentra-
tion of [3H]oestradiol-17B (0-030 nM) and
varying concentrations of non-radioactive
oestradiol-17B (0.031, 0 092, 0-153, 0-214,
0-276 and 61-2 nM) in a total volume of 1-2
ml. Dextran-coated charcoal suspension was
used to separate the bound and free fractions.
The receptor concentration was calculated by
Scatchard analysis (Scatchard, 1949).
The following paper describes a study in
which samples of tissues and cytosols were
exchanged between these and other labora-
tories (King et al., 1978).
Definitions of positive result.-The level of
receptor protein in the tumours assayed at
ICRF laboratories was expressed in terms of
the total protein concentration of super-
natant.
In Edinburgh, total protein concentration
was not initially estimated routinely, and the
level of receptor protein was therefore ex-
pressed in terms of wet-weight tumour
assayed. The "cut-off" points for each centre
was defined as follows:
Guy's/ICRF:
positive result
equivocal
negative
Edinburgh:
positive result
equivocal
negative
>10 fmol/mg protein
5-10 fmol/mg protein
< 5 fmol/mg protein
>0 5 fmol/mg wet wt
0-25-0-5 fmol/mg wet wt
<0-25 fmol/mg wet wt
These "cut-off" points are comparable: in
Edinburgh, when a tissue contained 0-25
fmol receptor activity/mg tissue, this corres-
ponded to -5 fmol/mg protein.
Clinical assessment.-A special pro-forma
was completed for each patient at entry into
the study, and at 3 and 6 months a question-
naire was sent to the clinician requesting in-
formation about the outcome of therapy.
Initially we planned to assess response to
therapy according to the British Breast
Group criteria (1974), but later agreed to use
the system recommended by the UICC Pro-
gramme on Clinical Oncology (Hayward et al.,
1977) and re-evaluated all patients accord-
ingly. This system stresses the need for accu-
rateassessmentbeforetreatmentisstarted (i.e.
the effects of previous therapy must be com-
plete, there must be evidence of progressive
disease, and the bulk of disease must be
evaluable and documented fully by clinical
measurement, photography and radiology).
The categories of response were defined as
follows:
Objective regression.-
(a) Complete response (CR)-disappear-
ance ofall known disease. In the case of
lytic bone metastases these must be
shown radiologically to have calcified.
(b) Partial response (PR)-a 50% or more
decrease in the sum of the products of
the perpendicular axes of measurable
lesions and objective improvement in
evaluable but non-measurable lesions;
no new lesions. It was not necessary for
every lesion to have regressed to qualify
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for partial response, but no lesion
should have progressed.
No change (NC).-Less than 50% decrease
or less than 25% increase in size ofmeasurable
lesions.
Progressive disease (PD).
(a) Mixed-some lesions regress while
others progress or new lesions appear.
(b) Failure-progression of some or all
lesions and/or appearance of new
lesions; no lesions regress.
At the end of the study, the records of all
patients were reviewed by an extramural
observer who at the time did not have know-
ledge of the result of the oestrogen-receptor
assay (R.D.R. for Edinburgh; M.M.R. for
Guy's).
RESULTS
One hundred and fifty-six patients were
accrued over a period of 30 months, but
37 were excluded after external review for
the following reasons:
22 were found to beunassessablebecause
the clinical records were inadequate, 1
tumour biopsy specimen was inadequate
on histological review, 5 patients were
on additive hormone therapy at the time
of biopsy, in 3 patients the assay was
invalid (for technical reasons) and in 6
patients material did not reach the
laboratory.
Of the 119 patients remaining, 80 had
tumours which contained measurable ER
protein (67%). The overall figures were
similar for both centres, and corresponded
to their normal findings. Menstrual status,
as in all other reported series, had a
marked effect, more positive assays occur-
ring in postmenopausal patients. The ma-
jority of biopsy specimens were from the
primary tumour, but some were ofsecond-
ary deposits. However, in this small
sample, site of biopsy did not influence
the incidence of positive assays (Table I).
Almost half of the patients (54) in-
cluded in the study had advanced localized
disease with no evidence of a distant
spread; the remainder had proven meta-
stases in the skeleton (30), lung (14), liver
(10) or in multiple systems (11).
TABLE I.-Positive receptor assay according
to menstrual status and site ofbiopsy. The
difference in the Guy's series between pre-
and postmenstrual groups is significant
(X2=6.25, P< O01). For this reason only
postmenopausal patients were analysed
for site. See text for defnition of positive
(+) and equivocal (+) assay
Premenopausal
Postmenopausal
Postmenopausal
Breast
Nodes
Skin
Guy's
Assav
,--T
+
0 10
4 16
4 26
2 9
0 4
2 3
4 16
Total +
15 5
57 37
72 42
32 21
7 3
18 13
57 37
Edinburgh
Assay
Total +
11 4
36 27
47 31
29
1
6
36
20
1
6
27
2 5
1 8
3 13
1
0
0
1
8
0
0
8
Histological review
One hundred and twenty-eight tumours
were available for histological assessment,
including material from some patients who
were omitted from the main analysis for
clinical reasons. Of these, 100 were from
postmenopausal patients and, when the
relationship between histological score and
ER measurement was analysed by a non-
parametric test for trend (Cox, 1969), it
was found that half the tumours in the
inadequate and doubtful histological cate-
gories (2, 3, 4) were ER-negative, com-
pared with only one fifth oftumours in the
other groups (5, 6, 7) (Table II).
TABLE II.-Theproportion ofER- tumours
according to histological score in post-
menopausal patients from both centres.
The sum of the T valuesfor Cox's testfor
trendfrom the two series gives a Z score of
2-06, significant at the 5% level when
referred to the normal distribution. Defini-
tion of ER- result in text
Histological score
Guy's Edinburgh Combined
2,3,4 5 6,7 2,3,4 5 6,7 2,3,4 5 6,7
ER- 6 5 6 5 1 3 11 6 9
Total 13 21 30 10 12 15 23 33 45
% 48 18 20
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Response to therapy
Combining the data from both centres,
119 assessable patients had been treated
by endocrine therapy. Of these, 26 were tm/mg premenopausal and were treated by protein
ophorectomy; the rest were postmeno-
pausal and were treated by hypophysec-
tomy or90Y implantation ofthe pituitary,
tamoxifen, stilboestrol, androgens (gener-
ally fluoxymesterone), prednisone or adre-
nalectomy. The numberofpatients in each
treatment group, and the clinical response
to therapy related to the result of the
oestrogen-receptor assay, are shown in
Table III. All responses were graded
according to the UICC criteria, and agreed E2R
upon at external review. m/mg ~~~~~Drtein
TABLE III.-The clinical response (CR-l
PR) according to result of ER assay in
116 patients treated by endocrine therapy.
The difference in response rate between
ER+(includingequivocal)andER-groups
is significant (X2=8-97, P<0.0025). See
textfor definitions ofclinical responseand
oestrogen-receptor status
Ophorectomy
Hypophysectomy
Stilboestrol
Tamoxifen
Androgens
Others
Total
No.
treated
26
18
24
34
12
5
119
ER+
6/9
3/10
7/19
6/24
1/8
1/3
24/73
ERI ER-
0/2 1/15
1/1 0/7
0/0 0/5
1/2 2/8
2/2 0/2
0/0 0/2
4/7 3139
Of the 80 patients who had measurable
ER protein in their tumours, 28 achieved
partial or complete remission of their
disease (35%). Only 3 (8%) of the 39
patients with undetectable oestrogen re-
ceptor responded to therapy. In the group
of patients treated by tamoxifen (gener-
ally at a dose of 30 mg/day) the response
rate was similar, whether ER protein was
present or absent from the tumour.
The absolute values of the oestrogen-
receptor concentration in the 44 patients
treated by endocrine surgery are shown in
Fig. 1. Response to ophorectomy was
associated with the highest levels of ER
GUYS EDINBURGH
OOPHORECTOMY
E2R
Fm/mg
wet wt
2-5-
0 5-
HYPOPHYSECTOMY
100-
50-
10-
150
E2R
fm/mg
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25-
05
FIG. 1.-ER (absolute values) for patients
from Guy's and Edinburgh treated by
endocrine surgery. * complete remissions;
* partial remission; M no change; C]
progressive disease. The abscissa represents
the cut-offpoint for each assay.
protein, but response to hypophysectomy
or any of the additive therapies was not
(Fig. 2).
DISCUSSION
The number included in this study
represents all eligible patients over a 30-
month period, but it is small because in
both centres many patients are treated by
chemotherapy or combinations of chemo-
therapy and endocrine therapy. It is note-
worthy that 23% ofall those referred were
withdrawn from the study after external
review. This partly reflects organizational
problems, but it is worth stressing that in
many cases loss was due to inadequate
clinical information.
It is of interest that the proportion of
ER- tumours was related to the histologi-
cal score. Although only one patient was
excluded because of a histologically in-
434
c- 5u0 rENDOCRINE THERAPY IN ADVANCED BREAST CANCER
EDINBURGH
STILBOESTROL
TAMOXIFEN
FIG. 2. ER (absolute values) for patients
from Guy's and Edinburgh treated by
hormones. Key as for Fig. 1.
adequate tumour biopsy specimen, a fur-
ther 11 patients had a doubtful histological
score (3 or 4) and no detectable ER pro-
tein. In addition, 3 patients who were
excluded from analysis for clinical reasons,
also had doubtfully adequate pathology
and ER- tumours. This could mean a
total loss to study of 10% (15/156) if more
stringent pathological criteria were ac-
cepted, which underlines the need for pro-
viding adequate tumour material for the
biochemist. Previously, Rosen et al. (1975)
have described low levels of oestrogen-
receptor activity in both primary and
metastatic tumours with low cellularity.
The overall response to therapy in our
study was 27%. Patients with ER+ tu-
mours were 4-5 times more likely (8-9
times in the ophorectomy group) to re-
spond than those with ER- tumours. In
general, patients with ER- tumours had
only an 8% chance of responding to en-
docrine therapy, compared with 33% in
ER+ tumours. This may not be true for
tamoxifen; in our study, although the
numbers were small, the response rates
were similar whether the receptor protein
was present or absent. In the overview by
McGuire et al. (1975), 47 patients had been
treated with anti-oestrogens, mainly naf-
oxidine, with an overall response of 29%,
and 18% in those patients whose tumours
were ER-. The relationship of response to
tamoxifen therapy and oestrogen-receptor
status is therefore not so certain, and
more data should be sought to determine
whether it is influenced by age, site of
disease or other parameters.
Our results are somewhat less encourag-
ing than those previously reported, but
provide further evidence that the oestro-
gen-receptor assay is a prognostic aid in
selecting certain forms of endocrine
therapy for patients with advanced breast
cancer. Nevertheless, it may not be justi-
fiable to perform an open biopsy for re-
ceptor assays in a patient being treated by
additive hormones, as the morbidity from
this procedure may be greater than that
from the therapy. On the other hand, it is
probably wrong to contemplate ablative
endocrine surgery for a patient whose
tumour does not contain ER protein.
With increasing use of non-endocrine
methods of treatment, it is now unlikely
that more data will be acquired on this
point.
In this study, we have tried to highlight
some of the organizational problems in-
volved if oestrogen-receptor assays were
to be offered as a service to all patients
with breast cancer. Whether such a service
is justifiable at present is in doubt, and
may have to await improvement in the
degree of prediction, possibly by the in-
clusion ofassays ofother receptor proteins.
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